Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Ovarian Neoplasms

Free Subscription 16.03.2026 1 Br J Cancer 1 Cancer Lett 6 Gynecol Oncol 1 Histopathology 1 Hum Pathol 1 Int J Oncol 1 J Clin Oncol 1 J Natl Cancer Inst 3 Oncogene 1 Oncol Rep

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Br J Cancer

1. MITCHELL AR, Chen Y, Pugliese G, Vino Flores G, et al
   Investigating PAK inhibition in combination with PD-1 blockade to enhance cytotoxic CD8+ T cell-mediated killing and suppress invasion of ovarian cancer cells.
   Br J Cancer. 2026 Mar 6. doi: 10.1038/s41416-026-03342.
   PubMed         Abstract available
   
   

   
   Cancer Lett

2. YOU J, Liu J, Bao Y, Wang L, et al
   Corrigendum to Cancer Lett. 385 (2017) 271-279.
   Cancer Lett. 2026 Mar 9:218274. doi: 10.1016/j.canlet.2026.218274.
   PubMed        
   
   

   
   Gynecol Oncol

3. LEE MW, Friedman EL, Erfani H, Keymeulen S, et al
   Assessment of survival and clinicopathologic characteristics associated with lymph node isolated tumor cells in epithelial ovarian cancer.
   Gynecol Oncol. 2026;207:50-56.
   PubMed         Abstract available
   
   
4. NAKAYAMA J, McGaughey M, Pindzola G, Miller E, et al
   Corrigendum to 'Machine-learning survival models for predicting time to recurrence in epithelial ovarian cancer' [Gynecologic Oncology 204 (2026) 184-193].
   Gynecol Oncol. 2026;207:48-49.
   PubMed        
   
   
5. HUI C, Mendoza MG, von Eyben R, Dorigo O, et al
   Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma?
   Gynecol Oncol. 2023;177:150-156.
   PubMed         Abstract available
   
   
6. LIM H, Ju Y, Kim SI, Park JH, et al
   Clinical implications of histologic subtypes on survival outcomes in primary mucinous ovarian carcinoma.
   Gynecol Oncol. 2023;177:117-124.
   PubMed         Abstract available
   
   
7. SPAGNOL G, Marchetti M, De Tommasi O, Vitagliano A, et al
   Simple rules, O-RADS, ADNEX and SRR model: Single oncologic center validation of diagnostic predictive models alone and combined (two-step strategy) to estimate the risk of malignancy in adnexal masses and ovarian tumors.
   Gynecol Oncol. 2023;177:109-116.
   PubMed         Abstract available
   
   
8. NASIOUDIS D, Fernandez ML, Wong N, Powell DJ Jr, et al
   The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
   Gynecol Oncol. 2023;177:86-94.
   PubMed         Abstract available
   
   

   
   Histopathology

9. ZOU YS, Mohammed SY, Zhu J, Dashti NK, et al
   Ovarian Sertoli-Leydig cell tumors with heterologous rhabdomyosarcoma: Clinicopathologic features and molecular analysis highlighting recurrent genetic alterations.
   Histopathology. 2026;88:985-1002.
   PubMed         Abstract available
   
   

   
   Hum Pathol

10. BUZA N, Sun T, Hui P
    Endometrial Carcinomas - Challenges and Updates on Selected Topics.
    Hum Pathol. 2025 Dec 11:106016. doi: 10.1016/j.humpath.2025.106016.
    PubMed         Abstract available
    
    

    
    Int J Oncol

11. MUKINOVIC E, Federmann S, Messling L, Sekeres M, et al
    Overcoming acquired doxorubicin resistance of ovarian carcinoma cells by verapamil?mediated promotion of DNA damage?driven cytotoxicity.
    Int J Oncol. 2026;68:48.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

12. APOSTOL AI, Gronwald J, Cybulski C, Kim RH, et al
    Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.
    J Clin Oncol. 2026 Feb 28:JCO2501648. doi: 10.1200/JCO-25-01648.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

13. SHERMAN ME, Sellers ME, Cronin KA
    Stat Bite: Recent trends in ovarian cancer among Non-Hispanic Black and Non-Hispanic White women.
    J Natl Cancer Inst. 2026;118:556.
    PubMed        
    
    

    
    Oncogene

14. PEI X, Wang F, Liu X, Lei Y, et al
    Core fucosylation of NCEH1 by FUT8 promotes progression of high-grade serous ovarian cancer by driving tumor-associated macrophage M2 polarization.
    Oncogene. 2026 Mar 5. doi: 10.1038/s41388-026-03703.
    PubMed         Abstract available
    
    
15. WEBB JD, Buensuceso A, Tomas EJ, Borrelli MJ, et al
    ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer.
    Oncogene. 2026 Mar 5. doi: 10.1038/s41388-026-03702.
    PubMed         Abstract available
    
    
16. EL BABA R, Haidar Ahmad S, Monnien F, Mansar R, et al
    Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells.
    Oncogene. 2023;42:3047-3061.
    PubMed         Abstract available
    
    

    
    Oncol Rep

17. ZHANG H, Dong R, Zhang P, Wang Y, et al
    [Retracted] Songorine suppresses cell growth and metastasis in epithelial ovarian cancer via the Bcl?2/Bax and GSK3beta/beta?catenin signaling pathways.
    Oncol Rep. 2026;55:80.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum